In a daring initiative to tackle soaring healthcare expenses, the US government is setting its sights on pharmaceutical companies, demanding significant reductions in drug prices. At the same time, India’s thriving generics market stands resilient and largely unaffected, prompting intriguing discussions about the shifting landscape of global pricing dynamics.